Literature DB >> 35622523

Balancer-assisted outcrossing to remove unwanted background mutations.

Katsufumi Dejima1, Shohei Mitani1.   

Abstract

Whole-genome sequencing analysis allows us to identify a large number of natural variants and genetic changes created by mutagenesis. For instance, the Million Mutation Project isolated many point mutant alleles, which are available from the Caenorhabditis Genetics Center. Although collections of such mutations are very useful for genetic studies, the strains are often sick because they have multiple other mutations than the mutation of interest. To utilize the strains, it is necessary to outcross with other strains to remove undesired mutations. We previously constructed an inversion balancer toolkit covering a large part of C. elegans genome. In contrast to classical translocation balancers that cover parts of two chromosomes, each balancer from the toolkit covers a part of a chromosome. We think this compactness is beneficial for outcrossing mutants containing multiple background mutations. Here, we show that the fluorescence inversion balancer can be practically useful for outcrossing in the case where researchers want to simply evaluate the phenotypes. Copyright:
© 2022 by the authors.

Entities:  

Year:  2022        PMID: 35622523      PMCID: PMC9047254          DOI: 10.17912/micropub.biology.000561

Source DB:  PubMed          Journal:  MicroPubl Biol        ISSN: 2578-9430


(A) Dissecting microscope view of freshly starved wild type worms (top), gk837385 worms before outcross (VC40832, middle), and gk837385 worms after outcross (FX31729, bottom). The panel of the gk837385 original strain (middle) has many unhatched eggs (arrows). The panels of wild type (top) and the outcrossed strain (bottom) have many small larvae (arrowheads). Insets: enlarged images of the boxed area. (B) Genomic loci covered by tmC18 . (C) The outcrossing scheme to segregate away unlinked mutations using the fluorescently labeled inversion balancer (shown by green). N2 males are first crossed to the fluorescently labeled inversion balancer strain to generate heterozygous tmC18[tmIs1200] /+ males (P0). Males resulting from this cross are then crossed to the ego-1 mutant hermaphrodites (F1). Venus-positive hermaphrodites resulting from the second cross are then self-fertilized (F2). Following self-fertilization, a non-Venus hermaphrodite is isolated (F3).

Description

In some situations, researchers may want to evaluate whether mutants of the Million Mutation Project (Thompson et al. 2013) show the intended phenotype or not. To utilize the strains, it is required to outcross with other strain to remove background mutations. In the case of deletion mutations, they can be identified by the difference in the size of the PCR bands when genotyping after outcrossing, which is relatively easy. However, the majority of the mutations in this collection are point mutations, and genotyping them by Sanger sequencing and/or restriction fragment length polymorphism (RFLP) analysis are required (Robinson et al. 2017). Alternatively, genotyping can be done by using allele-specific PCR (Chen and Schedl 2021) or commercial kits, such as the High Resolution Melting (HRM) analysis (Doyle et al. 2021). It should be noted that regardless of the method, one needs to pick and genotype many candidate strains, unless the mutation linked to a visible phenotype. The fluorescent balancer can distinguish heterozygosity of alleles in the covered region: fluorescent marker-negative siblings from the parent bearing mutation over the fluorescent balancer are homozygotes for the mutation of interest because recombination near the locus of interest occurs very rarely (Edgley et al. 2006). Theoretically, outcrossing can be achieved by selecting worms without fluorescence for cleaning background mutations not covered by the balancer. Importantly, the balancer-assisted approach does not require genotyping many candidate strains and is most useful in the following situations: (a) the mutation of interest has no visible phenotype, (b) the strain has unlinked deleterious mutations, and (c) there are unlinked mutations that may modify the phenotype of mutation of interest. Indeed, a previous study applied this approach using the qC1 balancer and provided a good example of the situation (c), where three of daf-2 mutant strains from the Million Mutation Project also contained daf-18 mutations that suppress the daf-2 mutant phenotypes (Bulger et al. 2017). We experimentally tested how practically useful outcrossing with a structurally defined inversion balancer that we previously created by CRISPR/Cas9 gene editing (Dejima et al. 2018) could be and provide an example where the balancer-assisted approach works on the situation (b). We focused on the ego-1 gene, which encodes an RNA-dependent RNA polymerase (Smardon et al. 2000). The null mutants for ego-1 show a sterile phenotype with a germline RNAi defect. When we ordered 23 mutants (see Reagents) from CGC, five strains (VC40084, VC40832, VC40259, VC20439, VC40175) were sick, and 3 of them (VC40084, VC40832, VC40259) were not able to be made frozen stocks on the first receipt. We ordered these three strains from CGC again. Two of the strains were frozen successfully, but one strain (VC40832) was difficult to freeze because it had mostly lethal embryos (Fig. 1A). We performed outcrosses of all strains once using a balancer tmC18[tmIs1200] that covers the ego-1 locus (Fig. 1B and C) (Dejima et al. 2018). For 22/23 strains, we obtained healthy worms by outcrossing. For example, for strain VC40832, the outcross improved its embryonic lethality (Fig. 1A, 99.37 ± 0.55 %, n = 20, and 0.18 ± 0.18 %, n = 9, for VC40832 and FX31729, the strain after outcross, respectively). However, for gk115395 a single outcross did not improve the small reduced brood size (303.8 ± 10.5, n = 4, and 67.6 ± 8.7, n = 4, for N2 and gk115395 , respectively) suggesting that either additional outcrossing should be performed or that the mutation causing the decreased brood size is covered by the inversion balancer. Alternatively, the reduced brood size could be an ego-1 phenotype. Importantly, analysis by Sanger sequencing revealed the presence of mutations in all 23 outcrossed strains. Therefore, outcrossing with a fluorescence balancer is practically effective if researchers look for a simple screening method. Although we only tried tmC18 in this study, one can do the same with other loci and balancers. In addition, while we performed only a single outcross in this study and was able to prepare healthy worms for further experiments, it is important that the process should be repeated to further replace the mutagenized genome with wild type sequences. If the mutants of interest have invisible phenotypes such as behavior abnormality, experiments are greatly enhanced to work with recombination-free balancers as we presented here. We note that there is a limitation of the balancer-assisted approach: the mutation of interest needs to be covered by one of the existing inversion balancers. The approach is most appropriate for removing unlinked mutations as unwanted mutations that are not covered by the balancer will be removed.

Methods

-Outcrossing with a balancer The original ego-1 mutants (VC strains) were provided by the Caenorhabditis elegans Genetics Center, which is supported by the National Institutes of Health National Center for Research Resources. To outcross the strains, males of heterozygotes for tmC18[tmIs1200] were crossed with each ego-1 mutant strain. Venus+ F2 hermaphrodites were singled, then their Venus- F3 progeny was further singled and propagated. To confirm the mutations are present in the outcrossed strains, Sanger sequencing was performed. The primers used for PCR amplification and sanger sequencing are listed in the ego-1 mutant strain list (see Reagents).

Reagents

-Balancer strain: FX30167: tmC18[tmIs1200(Pmyo-2::Venus)] I -ego-1 mutant strains: Original strain allele position Outcrossed strain Primers (PCR, Sanger seq.) VC40259 gk540555 7650738 FX31713 F26A3#F37R40, R40 VC40886 gk864727 7650888 FX31714 F26A3#F37R41, R41 VC20206 gk115390 7651213 FX31715 F26A3#F38R42, F38 VC20319 gk317493 7651478 FX31716 F26A3#F39R43, F39 VC30058 gk115391 7651882 FX31717 F26A3#F40R21, F40 VC40244 gk532049 7652169 FX31718 F26A3#F41R21, F41 VC40660 gk749674 7652199 FX31719 F26A3#F41R21, F41 VC41006 gk925207 7652313 FX31720 F26A3#F41R21, F41 VC20618 gk357146 7652424 FX31721 F26A3#F41R21, F41 VC40613 gk721963 7653391 FX31722 F26A3#F19R21, F44 VC40920 gk882383 7653502 FX31723 F26A3#F19R1, F44 VC40140 gk481348 7653535 FX31724 F26A3#F19R1, F44 VC20439 gk115393 7653805 FX31725 F26A3#F19R1, F45 VC40951 gk896494 7653809 FX31726 F26A3#F19R1, F45 VC30158 gk426642 7654398 FX31727 F26A3#F19R1, R1 VC20474 gk115394 7654992 FX31728 F26A3#F18R44, R44 VC40832 gk837385 7655076 FX31729 F26A3#F18R45, F18 VC40084 gk115395 7655149 FX31730 F26A3#F18R46, R46 VC20545 gk115397 7655230 FX31731 F26A3#F18R47, R47 VC40175 gk498425 7655401 FX31732 F26A3#F18R47, R47 VC40116 gk470185 7655705 FX31733 F26A3#F18R48, R48 VC40611 gk720210 7656073 FX31734 F26A3#F42R12, F42 VC40050 gk115401 7656215 FX31735 F26A3#F43R12, F43 -Oligonucleotides: Primer name Sequence 5’ > 3’ F26A3#F18 AAGCTCCACGAACTGTCATC F26A3#F19 AGGTGGAATCATTTCGCCAG F26A3#F37 GTTCCGACATGACGAGGAGT F26A3#F38 CTACCAGCTTGCGATGAACC F26A3#F39 GTAGTAGGTTTTGAGTGCGG F26A3#F40 CGTGCCCATTCGTCTAACAT F26A3#F41 TTACTATCACGTCCGTAACG F26A3#F42 CGACGTCTAACGTCATCCCA F26A3#F43 ACCTGCTGGTCGCAACTTCA F26A3#F44 CCAAGCATTGACCGTCCGAG F26A3#F45 GAAAGCATTTGTCTGTCCAG F26A3#R1 GGAATATGGCACCGATTCCT F26A3#R12 GTCACGTTCTGCTTCCATCT F26A3#R21 TCGCCAGTTCCAGTGGCATT F26A3#R40 GGTTCATCGCAAGCTGGTAG F26A3#R41 CCGCACTCAAAACCTACTAC F26A3#R42 ATGTTAGACGAATGGGCACG F26A3#R43 TCGCATATGACGTCATCGCA F26A3#R44 AGCGCGAATCAGTATCCAAC F26A3#R45 GGAATCGGTGAGCACACCCA F26A3#R46 TAGAAGAGCCTACCGAACGG F26A3#R47 CGTTAGACGTCGGAAGTCGG F26A3#R48 ATTGCGGCGATCCAGACATA

Original strain

allele

position

Outcrossed strain

Primers (PCR, Sanger seq.)

VC40259

gk540555

7650738

FX31713

F26A3#F37R40, R40

VC40886

gk864727

7650888

FX31714

F26A3#F37R41, R41

VC20206

gk115390

7651213

FX31715

F26A3#F38R42, F38

VC20319

gk317493

7651478

FX31716

F26A3#F39R43, F39

VC30058

gk115391

7651882

FX31717

F26A3#F40R21, F40

VC40244

gk532049

7652169

FX31718

F26A3#F41R21, F41

VC40660

gk749674

7652199

FX31719

F26A3#F41R21, F41

VC41006

gk925207

7652313

FX31720

F26A3#F41R21, F41

VC20618

gk357146

7652424

FX31721

F26A3#F41R21, F41

VC40613

gk721963

7653391

FX31722

F26A3#F19R21, F44

VC40920

gk882383

7653502

FX31723

F26A3#F19R1, F44

VC40140

gk481348

7653535

FX31724

F26A3#F19R1, F44

VC20439

gk115393

7653805

FX31725

F26A3#F19R1, F45

VC40951

gk896494

7653809

FX31726

F26A3#F19R1, F45

VC30158

gk426642

7654398

FX31727

F26A3#F19R1, R1

VC20474

gk115394

7654992

FX31728

F26A3#F18R44, R44

VC40832

gk837385

7655076

FX31729

F26A3#F18R45, F18

VC40084

gk115395

7655149

FX31730

F26A3#F18R46, R46

VC20545

gk115397

7655230

FX31731

F26A3#F18R47, R47

VC40175

gk498425

7655401

FX31732

F26A3#F18R47, R47

VC40116

gk470185

7655705

FX31733

F26A3#F18R48, R48

VC40611

gk720210

7656073

FX31734

F26A3#F42R12, F42

VC40050

gk115401

7656215

FX31735

F26A3#F43R12, F43

Primer name

Sequence 5’ > 3’

F26A3#F18

AAGCTCCACGAACTGTCATC

F26A3#F19

AGGTGGAATCATTTCGCCAG

F26A3#F37

GTTCCGACATGACGAGGAGT

F26A3#F38

CTACCAGCTTGCGATGAACC

F26A3#F39

GTAGTAGGTTTTGAGTGCGG

F26A3#F40

CGTGCCCATTCGTCTAACAT

F26A3#F41

TTACTATCACGTCCGTAACG

F26A3#F42

CGACGTCTAACGTCATCCCA

F26A3#F43

ACCTGCTGGTCGCAACTTCA

F26A3#F44

CCAAGCATTGACCGTCCGAG

F26A3#F45

GAAAGCATTTGTCTGTCCAG

F26A3#R1

GGAATATGGCACCGATTCCT

F26A3#R12

GTCACGTTCTGCTTCCATCT

F26A3#R21

TCGCCAGTTCCAGTGGCATT

F26A3#R40

GGTTCATCGCAAGCTGGTAG

F26A3#R41

CCGCACTCAAAACCTACTAC

F26A3#R42

ATGTTAGACGAATGGGCACG

F26A3#R43

TCGCATATGACGTCATCGCA

F26A3#R44

AGCGCGAATCAGTATCCAAC

F26A3#R45

GGAATCGGTGAGCACACCCA

F26A3#R46

TAGAAGAGCCTACCGAACGG

F26A3#R47

CGTTAGACGTCGGAAGTCGG

F26A3#R48

ATTGCGGCGATCCAGACATA

  8 in total

1.  EGO-1 is related to RNA-directed RNA polymerase and functions in germ-line development and RNA interference in C. elegans.

Authors:  A Smardon; J M Spoerke; S C Stacey; M E Klein; N Mackin; E M Maine
Journal:  Curr Biol       Date:  2000-02-24       Impact factor: 10.834

Review 2.  Genetic balancers.

Authors:  Mark L Edgley; David L Baillie; Donald L Riddle; Ann M Rose
Journal:  WormBook       Date:  2006-04-06

3.  An Aneuploidy-Free and Structurally Defined Balancer Chromosome Toolkit for Caenorhabditis elegans.

Authors:  Katsufumi Dejima; Sayaka Hori; Satoru Iwata; Yuji Suehiro; Sawako Yoshina; Tomoko Motohashi; Shohei Mitani
Journal:  Cell Rep       Date:  2018-01-02       Impact factor: 9.423

4.  Sequence determinants of the Caenhorhabditis elegans dopamine transporter dictating in vivo axonal export and synaptic localization.

Authors:  Sarah B Robinson; J Andrew Hardaway; Shannon L Hardie; Jane Wright; Ryan M Glynn; Daniel P Bermingham; Qiao Han; Sarah M Sturgeon; Phyllis Freeman; Randy D Blakely
Journal:  Mol Cell Neurosci       Date:  2016-11-30       Impact factor: 4.314

5.  The million mutation project: a new approach to genetics in Caenorhabditis elegans.

Authors:  Owen Thompson; Mark Edgley; Pnina Strasbourger; Stephane Flibotte; Brent Ewing; Ryan Adair; Vinci Au; Iasha Chaudhry; Lisa Fernando; Harald Hutter; Armelle Kieffer; Joanne Lau; Norris Lee; Angela Miller; Greta Raymant; Bin Shen; Jay Shendure; Jon Taylor; Emily H Turner; LaDeana W Hillier; Donald G Moerman; Robert H Waterston
Journal:  Genome Res       Date:  2013-06-25       Impact factor: 9.043

6.  Caenorhabditis elegans DAF-2 as a Model for Human Insulin Receptoropathies.

Authors:  David A Bulger; Tetsunari Fukushige; Sijung Yun; Robert K Semple; John A Hanover; Michael W Krause
Journal:  G3 (Bethesda)       Date:  2017-01-05       Impact factor: 3.154

7.  Chemical and genetic rescue of in vivo progranulin-deficient lysosomal and autophagic defects.

Authors:  James J Doyle; Claudia Maios; Céline Vrancx; Sarah Duhaime; Babykumari Chitramuthu; Hugh P J Bennett; Andrew Bateman; J Alex Parker
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-22       Impact factor: 11.205

8.  A simple one-step PCR assay for SNP detection.

Authors:  Jian Chen; Tim Schedl
Journal:  MicroPubl Biol       Date:  2021-06-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.